Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

Avidity Biosciences, Inc.’s RNA share price has surged by 11.33%, which has investors questioning if this is right time to sell.

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Dr. Khandros will remain on the board of directors of Nutcracker Therapeutics, and Cynthia Collins will serve as executive ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Flamingo Therapeutics ("Flamingo") announced today its participation in the following upcoming investor conferences: ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...

For investors interested in scheduling a one-on-one meeting with the Remix management team, please contact your Stifel representative.

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...